Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
Ye Guo(Army Medical University), Jin Li(Shanghai East Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Songhua Fan, Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Yanqiao Zhang(Harbin Medical University), Yan Wang(Capital Medical University), Weijie Zhang(Nanjing Medical University), Gang Wang(Wuhan University), Hui Zhou, Qi Xu(China Jiliang University), Yueyin Pan(University of Science and Technology of China), Jing Guo(Qingdao University), Weiguo Su(Tamedia (Switzerland)), Yang Luo(University of Illinois Urbana-Champaign), Wensheng Qiu(Qingdao University), Yue Ma(Dalian Ocean University), Panfeng Tan
Cited by 57
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412